Healthcare entity
Atea Pharmaceuticals is the most frequent co-covered peer, appearing in 1 of the 2 tracked stories. Each story carries 3.5 original sources on average, compared with 2.8 for the broader beat in this window. The clearest coverage concentration is market-trends: 1 of 2 stories, with the rest divided among 1 other category.
Last mentioned: Mar 5, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Atea Pharmaceuticals is the most frequent co-covered peer, appearing in 1 of the 2 tracked stories. Each story carries 3.5 original sources on average, compared with 2.8 for the broader beat in this window. The clearest coverage concentration is market-trends: 1 of 2 stories, with the rest divided among 1 other category. The 5 average consequence score is below the beat benchmark of 5.8 in the same window. We currently track 2 Healthcare stories that mention Rumble, all published on March 5, 2026.
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 25 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Rumble. Shared-story counts are live from our verified record — not editorial picks.
Earnings Release
Companies report Q4 and Full Year 2025 results, signaling a shift to 2026 commercial targets.
Fiscal Year End
Med-tech firms report record system utilization rates for the 2025 calendar year.
Clinical Enrollment
Atea Pharmaceuticals completes enrollment for the Phase 2 Hepatitis C (HCV) trial.
Reimbursement Milestone
Profound Medical receives expanded CPT code coverage for TULSA-PRO in the U.S.
CooperCompanies (NASDAQ: COO) reported fourth-quarter 2025 financial results that met analyst expectations, driven by consistent performance across its CooperVision and CooperSurgical business units. The results underscore the company's resilience in the medical device sector despite broader macroeconomic fluctuations.
Source: markets.financialcontent.com · markets.financialcontent.com
Atea Pharmaceuticals and Profound Medical headlined a series of Q4 2025 earnings reports, highlighting a shift toward commercial scaling in medical devices and late-stage clinical milestones in biotech. These results underscore a sector-wide focus on capital preservation and high-margin recurring revenue models.
Source: manilatimes.net · manilatimes.net
Rumble is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
